AI Article Synopsis
Article Abstract
To compare outcomes of mitral valve surgery through conventional left atriotomy and transeptal approach (TS). Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. Primary outcomes were operative mortality and permanent pacemaker (PPM) implantation; secondary outcomes were new onset of atrial fibrillation (AF), stroke and operative times. Sixteen articles met the inclusion criteria with 4537 patients. Cardiopulmonary bypass was longer with TS (weighted mean differences - 16.44 minutes [-29.53, -3.36], P = 0.01). Rates of PPM implantation (risk ratio 0.65 [0.47, 0.89], P = 0.007) and new onset AF (risk ratio 0.87 [0.78, 0.97], P = 0.02) were higher with TS. Subgroup analysis of isolated mitral valve surgery cohort showed no difference in operative times, mortality, new onset of AF, stroke, and PPM implantation. There is equal outcomes between both approaches during isolated mitral valve surgery; however, TS was associated with longer operative times and higher postoperative AF and PPM rates when pooling combined procedures. A large randomized controlled trial is required to confirm those findings.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cpcardiol.2020.100602 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Right atrial thrombus during transcatheter edge-to-edge mitral valve repair.
Eur Heart J Case Rep
January 2025
Department of Cardiology, Tokushima Red Cross Hospital, 103 Irinokuchi, Komatsushima, Tokushima 7730001, Japan.
Minimally Invasive Mitral Valve Repair with Intercostal Cryoablation: A Case Report.
Thorac Cardiovasc Surg Rep
January 2024
Department of Adult and Pediatric Cardiac and Vascular Surgery, University Hospital Giessen and Marburg Campus Giessen, Giessen, Hessen, Germany.
Minimally invasive lateral thoracotomies may cause severe postoperative pain and discomfort. We describe an intraoperative intercostal cryo-neuronal pain block as one possibility for postoperative pain relief. A 63-year-old male patient underwent minimally invasive mitral valve repair.
View Article and Find Full Text PDFDays at Home After Transcatheter Mitral Valve Repair Versus Medical Therapy Alone in Heart Failure.
J Am Heart Assoc
December 2024
Smith Center for Outcomes Research in Cardiology, Division of Cardiovascular Medicine, Department of Medicine Beth Israel Deaconess Medical Center Boston MA USA.
Background: Transcatheter edge-to-edge repair of the mitral valve (mTEER) reduced a hierarchical end point that included death and heart failure hospitalization in COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation Trial). However, the magnitude to which mTEER increases the number of days a patient spends at home (DAH) in the first few years after treatment, a patient-centered end point not captured routinely in clinical trials, has not been evaluated. We compared 1- and 2-year DAH among patients with functional mitral regurgitation and heart failure randomized to mTEER plus medical therapy versus medical therapy alone (control) by linking the COAPT trial to comprehensive health care claims data.
View Article and Find Full Text PDFComparative Analysis of Central and Noncentral Degenerative Mitral Regurgitation Treated With Transcatheter Mitral Valve Edge-To-Edge Repair.
Catheter Cardiovasc Interv
December 2024
Department of Structural Heart Disease, National Center for Cardiovascular Disease, China & Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Background: Mitral valve transcatheter edge-to-edge repair (M-TEER) was initially indicated for central degenerative mitral regurgitation (DMR) lesions, but advancements in technology have enabled successful treatment in an increasing number of noncentral DMR patients.
Aims: This study aims to compare procedural outcomes and prognosis between noncentral DMR patients, outside clinical trial anatomical criteria, and central DMR patients undergoing M-TEER.
Methods: Drug-refractory moderate-to-severe DMR patients treated with M-TEER at Fuwai Hospital from January 2021 to February 2024 were retrospectively analyzed.
Clinical feasibility study of transcatheter edge-to-edge mitral valve repair in dogs with the canine V-Clamp device.
Front Vet Sci
December 2024
Department of Clinical Sciences and James L. Voss Veterinary Teaching Hospital, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, United States.
Objective: To determine procedural feasibility, safety, and short-term efficacy in dogs with severe degenerative mitral regurgitation (MR) undergoing transcatheter edge-to-edge repair (TEER) with a canine-specific device.
Design: Prospective, single-arm (uncontrolled), single-institution clinical feasibility study.
Animals: Fifty client-owned dogs with severe degenerative MR operated over a 28-month period.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!